What is the efficacy of PrEP in preventing HIV infection?

Updated: Jul 27, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Interim CDC guidelines were issued in 2011 based on the multinational study called the Pre-exposure Prophylaxis Initiative (iPrEx) trial that found that once-daily emtricitabine plus tenofovir disoproxil fumarate (FTC-TDF) provided an additional 44% protection against HIV infection in a study population of 2499 high-risk, HIV-negative men or transgender women who have sex with men. [149]

Over a median 1.2 years of follow up, 36 patients in the FTC-TDF group and 64 in the placebo group became infected with HIV. All study subjects also received comprehensive prevention services that included monthly HIV testing, condom provision, counseling, and management of other STDs. [149]

Additional studies have been completed or are ongoing in serodiscordant heterosexual couples and intravenous drug users. [150, 151]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!